MARKET
IPO

BRVE

Braveheart Bio
BRVE
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-08-06
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-0.99~-0.87
-
-
1.06B~1.20B
-
2026-07-15
Public Filing
View Prospectus
Pending
Offering
Price Range: 15.00~17.00
Shares to be Issued: 18.75M
2026-08-05
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 70.65M
2026-08-06
Listed
Braveheart Bio Readies $300 Million IPO Plan
Seeking Alpha · 20h ago
About BRVE
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.

Webull offers Braveheart Bio stock information, including NASDAQ: BRVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRVE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRVE stock methods without spending real money on the virtual paper trading platform.